Additional Locations: Canada-ON-Mississauga
Diversity - Innovation - Caring - Global Collaboration - Winning Spirit - High Performance
At Boston Scientific, we’ll give you the opportunity to harness all that’s within you by working in teams of diverse and high-performing employees, tackling some of the most important health industry challenges. With access to the latest tools, information and training, we’ll help you in advancing your skills and career. Here, you’ll be supported in progressing – whatever your ambitions.
Process Engineering Associate, Co-op/New Grad
This position is a 12-month co-op/new grad/PEY placement beginning January 2027
About the role
The Process Engineering Associate is directly involved in providing product design and manufacturability input during concept and commercialization phases as well as actively participating in continuous improvement initiatives when scaling up existing manufacturing processes.
Work mode: At Boston Scientific, we value collaboration and synergy. This role follows an on-site work model requiring employees to be in our local office at least five days per week.
Sponsorship: Boston Scientific will not offer sponsorship or take over sponsorship of an employment visa for this position at this time.
Relocation: Relocation assistance is not available for this position at this time.
Your responsibilities will include:
Required qualifications:
Preferred qualifications:
Requisition ID: 635662
Minimum Salary: $[[cust_salaryMin]]
Maximum Salary: $[[cust_salaryMax]]
The anticipated compensation and the value of core and optional employee benefits offered by Boston Scientific (BSC) – see www.bscbenefitsconnect.com--will vary based on actual location of the position and other pertinent factors considered in determining actual compensation for the role. Compensation will be commensurate with demonstrable level of experience and training, pertinent education including licensure and certifications, among other relevant business or organizational needs.
Compensation for hourly, non-sales roles may also include variable compensation from time to time (e.g., any overtime and shift differential) and annual bonus target (subject to plan eligibility and other requirements).
Compensation for salaried, non-sales roles may also include variable compensation, i.e., annual bonus target and long-term incentives (subject to plan eligibility and other requirements).
Compensation for sales roles is governed by Sales Incentive Compensation Plan (which includes certain annual non-discretionary incentives based on predetermined objectives).
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
Boston Scientific designs and makes medical devices used in procedures across cardiology, endoscopy, urology, and neuromodulation. Its products help doctors diagnose and treat conditions by guiding minimally invasive interventions and delivering therapies inside the body, with revenue from hospitals and clinics. The firm differentiates itself through a broad, global portfolio and heavy ongoing investment in research and development to expand capabilities and address complex health issues. Its goal is to improve patient care by providing reliable, effective medical devices and solutions that enable clinicians to perform safer, more effective procedures while growing its business.
Company Size
10,001+
Company Stage
IPO
Headquarters
Marlborough, Massachusetts
Founded
1979
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Boston Scientific Recalls 199 Microcatheters Distributed to South African Hospitals. Thomas October 20, 2026 Boston Scientific Recalls 199 Microcatheters Distributed to South African Hospitals. Boston Scientific has recalled 199 Direxion and Direxion HI-FLO Torqueable Microcatheters distributed to healthcare facilities across South Africa, following a manufacturing issue that could affect the devices' movement during medical procedures. The recall, dated 20 October 2026, affects products supplied to healthcare facilities including Diagnostic Radiological Services, Groote Schuur Hospital, Netcare facilities, Life Wilgers Hospital, Life Peglerae Hospital, Capital Radiology and other healthcare providers. According to the supplier, the manufacturing issue may make it difficult to remove the affected microcatheter from its carrier hoop or to advance and withdraw it through a guide catheter. Increased resistance during these processes may damage the device, potentially affecting its performance during a procedure. The recalled products are single-lumen, multipurpose microcatheters used by healthcare professionals to access treatment sites in the peripheral vasculature during medical procedures. The supplier has identified life-threatening embolism as the most serious potential harm associated with a dysfunctional microcatheter. The likelihood of this occurring has been assessed as remote. The National Consumer Commission (NCC) has advised healthcare professionals to immediately discontinue use of the affected products. Healthcare facilities have also been advised to remove the affected devices from their inventories and segregate them in a secure location while awaiting their return to Boston Scientific. The NCC further advised healthcare professionals to consult the supplier's recall notice to verify whether products in their possession are affected by checking the relevant product and lot numbers. The recall applies to the identified Direxion and Direxion HI-FLO Torqueable Microcatheters distributed to healthcare facilities nationally. The NCC's guidance is directed at healthcare professionals and facilities handling the affected devices, with the immediate focus on preventing further use of products covered by the recall. Boston Scientific is the biomedical and biotechnology company supplying the recalled devices. The recall follows the identification of the manufacturing issue affecting removal from the carrier hoop and advancement or withdrawal through a guide catheter.
Boston Scientific shares have fallen 54.7% over the past year, against a 17.3% gain for the S&P 500, even as the medical device maker grew revenue 13.5% in the twelve months to June 2026. In August, a cyberattack disrupted its manufacturing and order shipments. Risk has risen because capital spending reached $2.72 billion, above the $2.15 billion spent on research. Research had led at every quarter end since at least September 2011. Most of the extra spending came in April to June, at $1.93 billion versus $245 million a year earlier. Free cash flow fell to $1.81 billion from $3.18 billion, while total debt rose to $12.6 billion from $12.0 billion. On July 29, management cut its 2026 revenue growth forecast to 6.0% from 7.8%. The next report, expected around October 28, 2026, covers the quarter the attack hit.
Ransomware attacks hit yearly high in August, says NCC Group. Wed, 7th Oct 2026 (Today) Ransomware attacks reached 1,073 in August, the highest monthly total of the year and 12% above the 960 recorded in July, according to NCC Group. The cyber security company's monthly threat intelligence findings also showed a change in the leading threat group. Qilin was responsible for 15% of all attacks, overtaking The Gentlemen. North America remained the most targeted region, accounting for 44% of attacks in August. Europe followed with 26%, continuing a pattern in which Western markets bore most of the reported incidents. Industrials remained the main target by sector, accounting for 31% of attacks in August, up from 28% in July. The increase underscores sustained pressure on businesses involved in infrastructure, manufacturing and related operations. The data points to continued disruption across large organisations. Incidents cited in the report included a customer data leak at Manchester Airports Group that affected car park, lounge, fast track bookings and in-airport WiFi systems, and an intrusion at US medical technology company Boston Scientific that disrupted manufacturing, shipping and customer order processing. Aurora case NCC Group also described a case handled by its Digital Forensics and Incident Response team involving the Aurora ransomware group and a transportation organisation. In the account, Aurora exploited a virtual private network and left a short ransom note on an encrypted hypervisor. The note said confidential files had been encrypted and instructed the victim to make contact through the Tor browser using a provided .onion link and access key. The case suggests data extortion has become a priority for the group alongside encryption and, in some cases, destruction. Aurora first emerged this year and has since targeted organisations in manufacturing, legal and research and development, the report said. The findings come as cyber security groups track how artificial intelligence is affecting both cyber attacks and defensive measures. NCC Group pointed to the recent Hugging Face incident as an example of concerns about the behaviour of advanced AI models, saying similar issues were prompting wider debate about policy and regulation. Matt Hull, vice president of cyber intelligence and response at NCC Group, said the latest figures suggested a sustained rise in ransomware activity rather than a one-off spike. "August was the second consecutive month of highest ransomware levels for the year, indicating a steady rise in global activity. A combination of factors is driving this increase, including rapid advancements in AI and ongoing geopolitical volatility, which are fuelling state-sponsored threats. "As the threat landscape evolves, organisations must ensure their resilience and response capabilities keep pace. "AI is becoming a powerful tool for defenders and attackers. As these technologies continue to advance, the most effective approach to protecting against cyber threats will be combining AI's speed and scale with human expertise and experience. Keeping people at the centre of cyber defence, while using technology responsibly, will be key to identifying and responding to cyber risk."
ShinyHunters expose 6.4M in attack on medical supplier McKesson. Source Originally from "ShinyHunters expose 6.4M in attack on medical supplier McKesson" by The Register - View original. Vendor risk governance failure: McKesson's 6.4M record breach exposes healthcare supply chain liability gaps. Why this matters at board and regulatory level. When ShinyHunters compromised McKesson - a critical medical supplier serving 3,300+ oncology providers across 29 states - the breach extended far beyond a single organization's data loss. The exposure of 6.4 million records spanning patient data, staff credentials, and healthcare provider contacts demonstrates a systemic governance failure: healthcare organizations lack binding contractual mechanisms to enforce, audit, and verify vendor security controls proportional to the sensitivity of data those vendors hold. The $55.2 million extortion demand reveals that threat actors now price attacks based on a vendor's position in the supply chain and the downstream liability exposure they create. This pricing model transforms vendor selection from a procurement decision into a board-level governance priority - yet most healthcare organizations remain unprepared to manage the cascading notification obligations, regulatory exposure, and liability allocation that follow a vendor breach of this scale. The supply chain leverage problem. McKesson's position as a critical infrastructure node in healthcare supply chains creates asymmetric risk exposure. A compromise at this level does not affect only McKesson's direct contractual relationships; it propagates through multiple layers of healthcare providers, patients, and staff. Yet the contractual frameworks governing vendor relationships typically fail to specify minimum security controls, real-time audit rights, or binding incident notification timelines. Most healthcare organizations discover - only after a breach occurs - that their vendor contracts lack clarity on who bears responsibility for notification costs, who funds regulatory remediation, and how liability is allocated if disclosure is delayed or incomplete. The concurrent breaches at Boston Scientific and Veradigm, both traced to compromised third-party vendor credentials, reveal a second structural weakness: credential hygiene and access control segregation across vendor ecosystems. When a single compromised credential grants access to multiple downstream systems, the breach becomes a supply chain cascade rather than an isolated incident. This pattern indicates that healthcare organizations have not implemented contractual requirements mandating multi-factor authentication, credential rotation, and access logging for third-party integrations. Under NIS2 and DORA frameworks, critical infrastructure operators and financial entities must assess and monitor supply chain security; healthcare organizations subject to similar regulatory expectations must translate these mandates into enforceable contractual language that specifies minimum technical controls, audit rights, and forensic disclosure obligations. Notification complexity and liability allocation. A breach affecting 6.4 million records triggers notification obligations under HIPAA, state breach notification laws, and potentially GDPR if European patients or providers are affected. However, contractual relationships between vendors and downstream customers often fail to allocate responsibility for notification timing, forensic disclosure, and regulatory reporting. Many healthcare organizations lack contractual clarity on whether their vendor must notify them within a specific timeframe, provide forensic details necessary for regulatory submissions, or assume liability for regulatory fines resulting from delayed or incomplete notification. This ambiguity creates operational chaos and legal exposure at the moment when coordinated, rapid response is most critical. The incident also exposes how vendor risk governance frameworks often overlook extortion as a distinct liability vector. A $55.2 million ransom demand creates pressure on the vendor to negotiate, potentially delaying breach disclosure to downstream customers and regulators. Contractual frameworks should explicitly prohibit vendors from negotiating ransom payments without notifying affected customers and should require vendors to maintain cyber liability insurance that covers both breach response costs and downstream customer notification obligations. Without these contractual anchors, healthcare organizations face scenarios where their vendor's negotiation decisions directly affect their own regulatory exposure and liability timeline. Cybersol's perspective: where governance frameworks break down. This incident reveals a critical distinction between technical security and governance-level risk management. The technical attack vector - credential compromise via a third-party vendor environment - is well-understood and preventable through standard access controls. The governance failure is contractual and organizational. Most healthcare vendor agreements were drafted before ransomware became a primary extortion mechanism, before supply chain attacks became the dominant attack pattern, and before regulators began holding organizations accountable for vendor security failures. Organizations typically overlook three specific risk layers: * Contractual specificity on security controls: Vendor contracts often reference "industry-standard security" or "reasonable safeguards" without defining what these terms mean operationally. Contracts should specify minimum technical controls (MFA, encryption, access logging), audit frequency, and remediation timelines for identified vulnerabilities. * Notification obligation clarity: Contracts should specify that vendors must notify the organization within 24-48 hours of discovering a breach, provide forensic details within 5 business days, and assume responsibility for notifying affected individuals if the vendor's negligence caused the breach. * Cyber liability insurance as a contractual requirement: Vendors should be required to maintain cyber liability insurance that covers breach response costs, notification expenses, and regulatory fines. This shifts financial risk to the vendor and creates an incentive for the vendor to maintain strong security controls. Most healthcare organizations have not integrated these requirements into their vendor management frameworks, leaving them exposed to the exact scenario McKesson's breach created: rapid escalation of liability, regulatory notification cascades, and contractual ambiguity about who bears the cost of remediation. Original source. The Register, "ShinyHunters expose 6.4M in attack on medical supplier McKesson" (September 10, 2026), reported by Connor Jones. Closing reflection. This incident demonstrates that vendor risk governance in healthcare remains reactive rather than preventive. Organizations should review the original article for specific technical details about the attack vector and credential compromise mechanisms. More importantly, they should use this incident as a trigger to audit their vendor contracts for explicit security requirements, notification obligations, liability allocation, and cyber insurance mandates. The governance failure here is not primarily technical - it is contractual and organizational. Healthcare boards should commission a vendor contract audit within the next 60 days, with specific focus on breach notification timelines, liability allocation, and cyber insurance requirements. The cost of updating vendor agreements is negligible compared to the regulatory exposure and notification costs that follow a breach of this scale.
FDA grants 510(k) clearance to SpaceOAR Flex Hydrogel for prostate radiotherapy. A limited market release of SpaceOAR Flex is expected to begin in the US later this year. The FDA has granted 510(k) clearance to the SpaceOAR Flex Hydrogel as a rectal spacer in men undergoing radiation therapy for .[1] The device is intended to temporarily position the anterior rectal wall away from the prostate during prostate cancer radiotherapy, with the goal of reducing the radiation dose to the rectum. The clearance expands Boston Scientific's SpaceOAR portfolio and follows earlier FDA clearances for SpaceOAR Hydrogel and SpaceOAR Vue Hydrogel. SpaceOAR Flex is designed with a flexible hydrogel delivery system that allows the physician to pause delivery, evaluate placement, and adjust delivery in real time, according to press communication from Boston Scientific. The system also uses a single-syringe delivery approach and is designed to reduce setup steps compared with the SpaceOAR Hydrogel and SpaceOAR Vue systems. "Rectal spacing has become an important tool for physicians seeking to limit radiation exposure to healthy tissue during prostate cancer treatment," said Ronald Morton, MD, chief medical officer, Urology, Boston Scientific, via press communication from Boston Scientific. "SpaceOAR Flex Hydrogel builds on our experience in this category and provides physicians with another option based on their clinical and workflow needs." The company also noted that SpaceOAR Flex is designed to be visible on computed tomography (CT) scans, including kV cone-beam CT, similar to SpaceOAR Vue. According to the company, this visibility is intended to facilitate contouring of the prostate and rectum during treatment planning and to assist with patient positioning during image-guided radiotherapy. The device is being assessed in the multicenter HYDROSPACE trial (NCT06451614). Preliminary results from the study will be presented at the 2026 American Society for Radiation Oncology Annual Meeting in Boston, Massachusetts. The randomized controlled trial is assessing the effectiveness and safety of the SpaceIT Hydrogel System for perirectal spacing in patients who are undergoing external beam radiotherapy for the treatment of low to intermediate risk prostate cancer. Participants in the control arm received either the SpaceOAR System or SpaceOAR Vue Hydrogel.[2] Boston Scientific said it expects to begin a limited US market release of SpaceOAR Flex later in 2026. SpaceOAR and SpaceOAR Vue will continue to be commercially available for rectal spacing. REFERENCES 2. SpaceIT Hydrogel System for Perirectal Spacing (HYDROSPACE). ClinicalTrials.gov. Last updated September 14, 2026. Accessed September 25, 2026.